Adult Primary Hepatocellular Carcinoma
31
0
0
23
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
13 trials with published results (42%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
19.4%
6 terminated out of 31 trials
79.3%
-7.2% vs benchmark
3%
1 trials in Phase 3/4
57%
13 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (31)
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
IMC-A12 in Treating Patients With Advanced Liver Cancer